Revolutionizing Patient Outcomes
Our proprietary technology platform solves the fundamental biological challenge of efficiently and safely trafficking biomolecules such as proteins, antibodies, peptides, and RNA therapeutics across the body’s protective epithelial barriers.
Core to our technology strategy is the integration of therapeutic biopharmaceuticals and microbially-inspired proteins that transit across the intestinal epithelial barrier using natural active, receptor-mediated processes.
Advantages of the AMT Technology Platform
Active vesicular transport vs passive diffusion
- Transport of large biologic therapeutics
- Significantly higher transport efficiency than passive diffusion
- Rapid uptake at luminal surface and release in GI tissue
Wide array of modalities yields many opportunities
- Technology platform is applicable to proteins including antibodies, peptides, and RNA therapeutics
- Leverages known or validated biologic therapeutics incorporating AMT technology
Optimally targets biological therapeutics to the site of disease
- Localization of the product to the GI tissue to directly treat local disease
- The technology also allows the therapeutic to be directed for systemic distribution
Our technology platform is applicable to full-length proteins, peptides, full-length antibodies, antibody fragments, RNA therapeutics, and other molecular modalities.
AMT Carrier
GI tissue selective
- Localized to lamina propria
- Enhanced efficacy from direct access to target cells
- Improved safety due to minimal drug in blood
Systemic distribution
- Passes through GI tissue to the bloodstream
- Native, unmodified products
- Efficacy similar to injectables
- Improved safety with daily oral dosing
Scientific Publications & Presentations
AMT-101
Efficacy, Safety, and Tolerability of AMT-101: A Gut Selective Oral IL-10 Fusion in the Phase 2 FILLMORE Trial of Patients
Vipul Jairath, Brian Bressler, Mark S. Silverberg, Li-Yin Lee, Kyler A. Lugo, Rafael Mayoral Monibas, ThamilAnnamalai, J. Andrew Whitney, Emily Y. Weng, Bittoo Kanwar, Silvio Danese, Brian Feagan
Poster presentation at European Crohn’s and Colitis Organisation (ECCO) ’23 Congress
AMT-101, a Gut Selective Oral IL-10 fusion: Results from a Phase 1b Study in Patients with Active Ulcerative Colitis
Maximillian Posch, Raisa Tanase, Konstantine Maisaia, Alina Jucov, Christian Geier, Drew Hotson, Omar Hamdy, J. Andrew Whitney, Marvin Garovoy, Bittoo Kanwar, and Stefan Schreiber
Poster at 16th Congress of European Crohn’s and Colitis Organisation (ECCO), July 2021 (virtual)
A Novel Fusion of IL-10 Engineered to Traffic across Intestinal Epithelium to Treat Colitis
Nicole C. Fay, Baby-Periyanayaki Muthusamy, Linh P. Nyugen, Radhika C. Desai, Alistair Taverner, Julia MacKay, Minji Seung, Tom Hunter, Keyi Liu, Apurva Chandalia, Michael P. Coyle, Hyojin L. Kim, Sally Postlethwaite, Khushdeep Mangat, Lisa Song, Elbert Seto, Aatif Alam, Charles V. Olson, Weijun Feng, Maziyar Saberi, Tahir A. Mahmood and Randall J. Mrsny
The Journal of Immunology November 4, 2020
AMT-101: an oral human IL-10 fusion protein
Oral presentation at European Crohn’s and Colitis Organisation (ECCO), February 2020 (Vienna, Austria)
AMT-126
AMT-126: A novel oral GI-selective fusion protein delivering IL-22 to support mucosal homeostasis & epithelial barrier integrity
Kyler Lugo, Baby-Periyanayaki Muthusamy, Ezhil Amirthalingam, Rita Aguilera, Jessie (Zhiheng) Jia, Thamil Annamalai, Barbara Mittleman, Derek Maclean, Sally Postlethwaite, Omar Hamdy, Drew Hotson, Randall Mrsny, J. Andrew Whitney
Oral presentation and poster at FOCIS Annual Meeting, June 2022 (San Francisco, CA)
AMT Platform Technology
GRP75 as a Functional Element of Cholix Transcytosis
Keyi Liu, Tom Hunter, Alistair Taverner, Kevin Yin, Julia MacKay, Kate Colebrook, Morgan Correia, Amandine Rapp, and Randall J. Mrsny
Tissue Barriers 2022
Deep Mechanisms of Oral Delivery and Biomolecular Transport of Biopharmaceuticals
R.J. Mrsny.
Oral presentation at TIDES: Oligonucleotide and Peptide Therapeutics Annual Meeting, September 2020 (virtual)
A Clinical Assessment of Delayed-Release Coated Capsule Compositions for Regional Gastrointestinal Delivery using Gamma Scintigraphy
Chris Roe, Beth Brickhill, Litza Mckenzie, Simon Yau, john McDermott, Steve King and Derek Maclean
Oral presentation at Controlled Release Society Annual Meeting, June 2020 (virtual)
Cholix protein domain I functions as a carrier element for efficient apical to basal epithelial transcytosis.
A. Taverner, J. MacKay, F. Laurent, T. Hunter, K. Liu, K. Mangat, L. Song, E. Seto, S. Postlethwaite, A. Alam, A. Chandalia, M. Seung, M. Saberi, W. Feng, and R.J. Mrsny.
Tissue Barriers. 2020; 8(1): 1710429.
